Pomegranate Health GLP-1 prices
Telehealth with compounded semaglutide and tirzepatide from state-licensed pharmacies, no membership fee, plus brand prescriptions billed to insurance (compounded is not FDA-approved). Pomegranate Health has 2 sourced self-pay GLP-1 offers here. Advertised entry prices: Compounded semaglutide from $129/mo; Compounded tirzepatide from $159/mo. Plan terms, fees and the check date are listed with each quote.
Search by medication, provider or treatment goal. Examples follow.
Tirzepatide · Compounded
1 offers · US self-pay
- Maintenance priceView offer
No separate dose price verified
Price conditions & source
Advertised price: starting price; provider review, medication and delivery included, no membership fee
Weekly injection; not offered in California, Iowa or Wisconsin. Pomegranate's pricing page shows a one-month starter at $149, below this product page's $159. Compounded; not FDA-approved.
Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the provider. A listed offer does not confirm eligibility or stock.
Read the advertised-price source
Read prices in context. Compare the same product, dose, and payment terms. A prepaid monthly rate is not a monthly payment. Cost order uses current, recently checked quotes with documented supply periods, converted to 30 days. Other prices are unranked references. Dose changes, introductory terms and added fees affect what you pay.
Missing prices are not estimated. A listed maintenance dose is not a dosing recommendation.
The FDA declared the tirzepatide (December 2024) and semaglutide (February 2025) shortages resolved, ending the exemption that let pharmacies mass-produce compounded copies, and the 503A/503B enforcement-discretion grace periods ended in 2025. The FDA is now actively enforcing (warning letters and takedowns, including a September 2026 warning letter to Empower Pharmacy, a large compounder, over products it called essentially copies of approved semaglutide and tirzepatide), and in 2026 proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list (the public comment period, extended 30 days, closed July 30, 2026; a final decision is pending). Liraglutide is different: it is still on the FDA drug shortage list (brand Victoza and Saxenda in limited supply, generics available, as of September 2026). Compounded GLP-1s are not FDA-approved and are now generally limited to narrow, patient-specific 503A prescriptions, so broad low-cost availability has largely wound down. They also carry safety risks the branded products do not: FDA adverse-event reports, at least one sterility recall (ProRx, October 2025), and counterfeit product found in the US supply chain, so a low price is not a low-risk signal. Prices and availability below may lag these changes; confirm current terms with the provider.
Pomegranate Health GLP-1 cost: common questions
How much does semaglutide cost through Pomegranate Health?
Compounded semaglutide: from $129/mo (starting price; provider review, medication and delivery included, no membership fee). Checked Oct 21, 2026; each quote links its source in the table. Compounded semaglutide is not an FDA-approved product.
How much does tirzepatide cost through Pomegranate Health?
Compounded tirzepatide: from $159/mo (starting price; provider review, medication and delivery included, no membership fee). Checked Oct 21, 2026; each quote links its source in the table. Compounded tirzepatide is not an FDA-approved product.
Does Pomegranate Health offer FDA-approved GLP-1 medication or compounded versions?
The Pomegranate Health offers tracked here are compounded: Compounded semaglutide; Compounded tirzepatide. Compounded GLP-1s are not FDA-approved products and are not reviewed by the FDA for safety, effectiveness, or quality.
When were Pomegranate Health prices last checked?
Each quote carries its own check date and links the page it was read from: Oct 21, 2026 for the offers here. A quote not rechecked within 21 days is kept as a dated reference and is no longer stated as a current price.